Brought to you by 
Merck, Pfizer team up on Phase III trials and future commercialization of Pfizer's SGLT2 inhibitor for Type II diabetes
31 May 2013
Executive Summary
Merck & Co. Inc. and Pfizer Inc. have entered into a worldwide (excluding Japan) collaboration surrounding the development and commercialization of Pfizer’s oral sodium-dependent glucose cotransporter (SGLT2) inhibitor ertugliflozin (PF04971729), which will enter Phase III trials for Type II diabetes later this year.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com